Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BKLC | 46.91 | 0.17 | +0.36% |
| BNY Mellon US Large Cap Core Equity ETF (BKLC) | |||
| PSCQ | 31.65 | 0.01 | +0.03% |
| Pacer Swan SOS Conservative (October) ETF (PSCQ) | |||
| BPAY | 24.41 | N/A | N/A |
| iShares FinTech Active ETF (BPAY) | |||
| IEUS | 70.37 | -0.96 | -1.35% |
| iShares MSCI Europe Small-Cap ETF (IEUS) | |||
| XRT | 89.50 | -1.57 | -1.72% |
| State Street SPDR S&P Retail ETF (XRT) | |||
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +7.54% | ||
| ROIV - IMVT | 64% Loosely correlated | +6.17% | ||
| LXEO - IMVT | 50% Loosely correlated | -0.52% | ||
| KURA - IMVT | 48% Loosely correlated | +6.91% | ||
| XNCR - IMVT | 47% Loosely correlated | +4.99% | ||
| SYRE - IMVT | 46% Loosely correlated | +7.53% | ||
More | ||||
a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.
Industry Biotechnology
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 226 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 226 cases the stock moved lower. This puts the odds of a downward move at 86%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Oscillator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.